RAPT — Rapt Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $123.03m
- -$56.25m
- 37
- 43
- 50
- 39
Annual balance sheet for Rapt Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 112 | 190 | 249 | 159 | 231 |
| Prepaid Expenses | |||||
| Total Current Assets | 116 | 193 | 253 | 162 | 235 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.98 | 2.74 | 9.48 | 7.68 | 4.7 |
| Other Long Term Assets | |||||
| Total Assets | 119 | 199 | 266 | 173 | 240 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 11.7 | 9.6 | 14.2 | 21.8 | 48.4 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 14.8 | 12.3 | 21 | 26.3 | 50.4 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 104 | 186 | 245 | 147 | 190 |
| Total Liabilities & Shareholders' Equity | 119 | 199 | 266 | 173 | 240 |
| Total Common Shares Outstanding |